Insulin Isophane

Introduction Overview

Generic Name

insulin isophane

Brand Name

Humulin N

Dosage Form

injectable suspension

Drug Class

Insulin

Pharmacokinetics

Absorption:
Humulin N, insulin isophane, is an intermediate-acting insulin formulated as a suspension of insulin bound to protamine sulfate. Following subcutaneous administration, the protamine complex delays insulin absorption, resulting in a slower onset compared to regular insulin. The onset of action typically occurs 2 to 4 hours after injection. Absorption can be affected by factors such as injection site (abdomen, thigh, upper arm), blood flow, temperature, and physical activity. Increased blood flow (e.g., exercise) or warmer temperature can accelerate absorption, while cold or scarred tissue can slow it. The absorption variability is higher than that of long-acting insulin analogs.

Distribution:
Once absorbed into the bloodstream, insulin distributes primarily within the extracellular space to target tissues such as skeletal muscle, adipose tissue, and the liver. Insulin does not bind extensively to plasma proteins, resulting in rapid access to insulin receptors. The volume of distribution is roughly equivalent to plasma volume since insulin acts primarily on cell surface receptors. Metabolic clearance is rapid, but the intermediate action of Humulin N is maintained due to the prolonged absorption from the injection depot.

Metabolism:
Insulin is extensively metabolized by insulinases present in liver, kidney, and muscle tissues. Approximately 60% of insulin is metabolized in the liver, where it undergoes receptor-mediated endocytosis and lysosomal degradation. The kidneys also contribute significantly to insulin metabolism and clearance, especially for circulating insulin. Humulin N’s protamine-bound form prolongs receptor exposure and delays peak action but does not alter hepatic or peripheral metabolism.

Elimination:
The elimination half-life of insulin in plasma is short, generally in the range of minutes; however, the effective biological duration following subcutaneous Humulin N injection is prolonged (12 to 18 hours) due to slow absorption from the injection site. Insulin degradation products are ultimately excreted via the kidney. Renal impairment can lead to decreased insulin clearance and prolonged hypoglycemic effects. The elimination phase clinically corresponds to the gradual decrease in insulin plasma levels after peak activity, contributing to its intermediate-acting profile.

Dosage Forms

Available Dosage Forms:
Humulin N is available as an injectable suspension for subcutaneous use provided in:
- Vials: 100 units/mL (10 mL vials)
- Prefilled pen devices: Humulin N KwikPen containing 100 units/mL insulin isophane suspension

Dosages for Adults and Adolescents:
Dosing is individualized based on blood glucose monitoring, dietary intake, and physical activity. Typical dosing initiates at approximately 0.2 to 0.6 units/kg/day divided into basal (intermediate-acting insulin such as Humulin N) and bolus insulin. Humulin N is generally administered once or twice daily. The dosing schedule aims to provide basal insulin coverage to control fasting blood glucose and complement rapid-acting prandial insulin.

Specific Patient Populations:
- Pediatric patients: Approved for use in children and adolescents with diabetes mellitus. Dose titration is important to avoid hypoglycemia.
- Pregnancy: Insulin requirements may vary; use only under medical supervision.
- Renal and hepatic impairment: Adjustment may be necessary due to altered insulin clearance.
- Elderly: Potential increased sensitivity to insulin; careful dose titration recommended.

Guidelines emphasize using Humulin N as part of a comprehensive diabetes management program including diet, exercise, and regular glucose monitoring.

Mechanism Of Action

Humulin N's primary mechanism is the replacement of endogenous insulin, a peptide hormone essential for glucose homeostasis. Insulin binds specifically to insulin receptors (a tyrosine kinase receptor) on target cell membranes, initiating receptor autophosphorylation and activation of intracellular signaling cascades. The activated receptor phosphorylates insulin receptor substrates (IRS), which subsequently activate phosphatidylinositol 3-kinase (PI3K) and downstream protein kinase B (Akt).

These signaling events facilitate translocation of glucose transporter 4 (GLUT4) vesicles to the plasma membrane particularly in muscle and adipose cells, thereby increasing glucose uptake from the bloodstream. Additionally, insulin promotes glycogen synthesis by activating glycogen synthase and inhibiting glycogen phosphorylase. It also reduces hepatic gluconeogenesis and lipolysis, further contributing to lowering plasma glucose levels.

Humulin N is formulated with protamine to delay absorption and prolong duration of action, providing intermediate basal insulin coverage to control blood glucose fluctuations between meals and overnight. This sustained action contrasts with rapid-acting insulins that manage postprandial hyperglycemia.

Clinical studies have demonstrated that Humulin N effectively maintains glycemic control in type 1 and type 2 diabetes. Compared with other basal insulin formulations, Humulin N’s pharmacokinetic profile allows flexible dosing intervals but has greater variability and risk of hypoglycemia compared to long-acting analogs. Research continues to evaluate optimizations in formulation and delivery to enhance efficacy and safety.

Pharmacological Actions

Replacement of endogenous insulin to regulate carbohydrate metabolism
Lowers blood glucose by enhancing peripheral glucose uptake
Suppresses hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis
Promotes glycogen synthesis and storage in muscle and liver
Inhibits lipolysis, reducing free fatty acid levels
Facilitates amino acid uptake and protein synthesis
Intermediate duration of action provides basal insulin effects
Delays insulin absorption via protamine binding for prolonged glycemic control
Reduces hyperglycemia-associated complications by maintaining glycemic targets
Acts via insulin receptor tyrosine kinase signaling pathways
Modulates metabolic gene expression impacting lipid and glucose metabolism
Improves overall metabolic homeostasis in diabetic patients
Helps control both fasting and between-meal blood glucose levels
Aids in weight regulation by preventing catabolic states due to insulin deficiency

Therapeutic Or Clinical Uses

Management of type 1 diabetes mellitus for basal insulin replacement
Management of type 2 diabetes mellitus when oral agents alone do not provide adequate glycemic control
Maintenance of blood glucose levels in diabetic children and adolescents
Used in combination with rapid-acting insulin to optimize glycemic control
Control of fasting and between-meal hyperglycemia
Adjunct therapy in patients requiring insulin for glycemic stabilization
Treatment of gestational diabetes when insulin therapy is indicated
Management of hyperglycemia in diabetic ketoacidosis stabilization protocols
Control of blood glucose in patients with pancreatic insufficiency leading to insulin deficiency
Used as basal insulin therapy in insulin pump alternative regimens (not for pump use but as background insulin support)
Off-label use in certain cases requiring insulin for glucose control as part of complex metabolic disease management
Treatment to reduce risks of diabetes-related microvascular and macrovascular complications

Side Or Adverse Effects

Hypoglycemia—most common adverse effect, ranging from mild to severe episodes
Allergic reactions including injection site redness, swelling, itching, or rash
Lipodystrophy at injection sites such as lipoatrophy or lipohypertrophy
Weight gain related to improved metabolic control and anabolic effects of insulin
Fluid retention leading to edema and potential heart failure exacerbation
Hypokalemia causing muscle cramps, weakness, and arrhythmia risk
Injection site reactions including pain or irritation
Rare systemic hypersensitivity reactions such as anaphylaxis
Rare occurrence of insulin antibody formation affecting insulin action
Peripheral edema and congestive heart failure risk when combined with thiazolidinediones
Skin thickening or hollowing at repeated injection sites
Transient visual disturbances related to rapid glucose changes
Dizziness, headache, and irritability secondary to hypoglycemia
Potential for localized infections if injection site hygiene is inadequate

Precautions

Do not use during episodes of hypoglycemia; avoid administration if blood sugar is low
Rotate injection sites regularly to minimize risk of lipodystrophy
Monitor potassium levels as insulin treatment may cause hypokalemia
Caution with patients having hepatic or renal impairment due to altered insulin metabolism
Adjust dose carefully during illness, stress, pregnancy, or changes in activity level
Patients must be educated on symptoms and management of hypoglycemia
Avoid alcohol consumption which can potentiate hypoglycemia
Use hygienic injection techniques to prevent infections
Do not mix Humulin N with insulin pumps or intravenous administration
Careful monitoring required when used with other antidiabetic agents, especially thiazolidinediones
Regularly monitor blood glucose and adjust dose accordingly
Ensure patients carry fast-acting carbohydrate sources to manage hypoglycemic episodes
Keep emergency glucagon kits available for severe hypoglycemia
Pregnancy and lactation require close medical supervision and dose modifications
Patients with cardiovascular disease should use insulin with caution

Warnings

Risk of severe hypoglycemia, which can be life-threatening if untreated
Never share insulin pens or syringes to prevent transmission of infections
Do not use if insulin suspension appears clear or contains particulate matter other than normal cloudiness
Use cautiously in patients with hypokalemia or predisposition to low potassium
Insulin overdose can cause coma, seizures, or death
Adjust dose carefully during periods of illness, surgery, or stress to prevent hypo- or hyperglycemia
Avoid driving or operating machinery until individual response to insulin is known
Increased risk of heart failure when used with thiazolidinediones
Hypersensitivity reactions can be severe and require immediate medical attention
Changes in insulin brand or formulation necessitate close glucose monitoring
Abrupt discontinuation may lead to diabetic ketoacidosis
Do not inject into muscle or vein; only subcutaneous administration is recommended
Store insulin properly to avoid loss of potency and ensure efficacy
Avoid exposure of insulin to freezing temperatures or excessive heat
Patients should wear medical identification indicating they are diabetic

Contraindication

Known allergy or hypersensitivity to insulin isophane or any excipients
During episodes of hypoglycemia or low blood sugar
Use of insulin pumps for Humulin N administration (not designed for pump infusion)
Severe hypokalemia without appropriate potassium replacement therapy
Patients with hypersensitivity reactions to protamine or related compounds
Uncontrolled hypoglycemia or hypoglycemia unawareness
Incompatible combination with other insulin formulations unless supervised by healthcare provider
Acute episodes of diabetic ketoacidosis requiring intravenous insulin
Patients unable to self-monitor blood glucose or comprehend dosing instructions
Contraindicated for intravenous or intramuscular administration
Severe liver or kidney impairment without medical supervision
Use in neonates and infants without appropriate medical guidance
Known allergy to preservatives or additives in the specific product formulation
Use during active systemic infections that may affect insulin requirements without close monitoring
Do not use expired or visibly contaminated insulin products

Drug Interactions

Beta-blockers may mask symptoms of hypoglycemia and impair recovery
Thiazide diuretics and corticosteroids may reduce insulin effectiveness, causing hyperglycemia
Alcohol can potentiate hypoglycemic effects and cause unpredictable blood glucose fluctuations
Oral antidiabetic drugs such as pioglitazone or rosiglitazone can increase risk of heart failure when combined with insulin
ACE inhibitors may enhance insulin sensitivity leading to increased hypoglycemia risk
Salicylates and non-steroidal anti-inflammatory drugs may increase insulin activity and hypoglycemia risk
Sympathomimetics may impair glucose tolerance and counteract insulin effects
MAO inhibitors can potentiate hypoglycemia by enhancing insulin action
Somatostatin analogs may inhibit insulin secretion but can complicate insulin dosing
Fluoroquinolones have potential to cause hypoglycemia or hyperglycemia in insulin-treated patients
Concomitant use of lithium can enhance hypoglycemia due to altered carbohydrate metabolism
Potassium-depleting agents may aggravate hypokalemia caused by insulin therapy
Thyroid hormones can alter insulin requirements due to metabolic rate changes
Estrogens and oral contraceptives can change insulin needs by affecting glucose metabolism
Drugs causing hypoglycemia unawareness (e.g., clonidine) may mask early signs of low blood sugar

Preparations Of The Drug

Humulin N (Insulin isophane suspension) injectable vial 100 units/mL (10 mL)
Humulin N KwikPen prefilled disposable insulin pen device containing 3 mL (300 units) of insulin isophane suspension
Available in U-100 insulin concentration standardized formulation
Kept as cloudy suspension requiring resuspension by rolling and inverting before injection
Preservatives included to maintain sterility and shelf-life
Provided with specific needles compatible only with the pen device for accurate dosing
Packaged in tamper-evident containers with clear dosing instructions
No admixture with other insulins in the same syringe except as specifically instructed
Storage instructions include refrigeration (2–8°C) prior to first use and room temperature use after opening per guidelines
Discard vial or pen after specified days in use to maintain product integrity
Manufactured under sterile conditions to prevent contamination
Instructions for use include priming of pen device and rotating injection sites
Supplied with detailed patient information leaflets and compatibility data
Available from multiple manufacturers under licensed production agreements
Adjunct packaging includes sharps disposal containers and educational materials for injection technique